Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.

Journal of medical economics

Volumn 16, Issue 2, 2013, Pages 318-326

  Pettigrew, Martine ^a   Garces, Kirsten ^b   Deuson, Robert ^b   Kassis, Jeannine ^b   Laroche, Vincent ^b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN; ROMIPLOSTIM; THROMBOPOIETIN;

ARTICLE; CANADA; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG EFFECT; ECONOMICS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; OUTCOME ASSESSMENT; THROMBOCYTE;

BLOOD PLATELETS; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; OUTCOME ASSESSMENT (HEALTH CARE); PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUEBEC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN;

EID: 84879019802     PISSN: None     EISSN: 1941837X     Source Type: None    
DOI: 10.3111/13696998.2012.756400     Document Type: Article

References (0)